SARS-CoV-2 in Captive Nonhuman Primates, Spain, 2020–2023
David Cano-Terriza
, Adrián Beato-Benítez, Leira Fernández-Bastit, Joaquim Segalés, Júlia Vergara-Alert, Eva Martínez-Nevado, Andrea Carretero, Dietmar Crailsheim, Pilar Soriano, Javier Planas, Mario Torro, and Ignacio García-Bocanegra
Author affiliations: Universidad de Córdoba, Córdoba, Spain (D. Cano-Terriza, A. Beato-Benítez, I. García-Bocanegra); CIBERINFEC ISCIII, Madrid, Spain (D. Cano-Terriza, I. García-Bocanegra); Universitat Autònoma de Barcelona, Barcelona, Spain (L. Fernández-Bastit, J. Segalés, J. Vergara-Alert); Zoo Aquarium de Madrid, Madrid (E. Martínez-Nevado); Centro de Rescate de Primates RAINFER/Fundación Chimpatía, Madrid (A. Carretero); Fundació Mona, Girona, Spain (D. Crailsheim); Río Safari Elche, Alicante, Spain (P. Soriano); Oasis Wildlife Fuerteventura, La Lajita, Canary Islands, Spain (J. Planas); Terra Natura Benidorm, Benidorm, Spain (M. Torro)
Main Article
Figure 2
Figure 2. Virus neutralization tests conducted for 2 SARS-CoV-2–seropositive gorillas in study of captive nonhuman primates, Spain, 2020–2023. Serum samples from 2 gorillas tested positive for SARS-CoV-2 antibodies by ELISA. Virus neutralization tests were performed; 50% neutralizing antibody titers were 1:131.4 for G1 and 1:191.9 for G2 serum samples. G1, gorilla 1; G2, gorilla 2.
Main Article
Page created: April 09, 2024
Page updated: May 22, 2024
Page reviewed: May 22, 2024
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.